Erratum: A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis (Blood (2017)130: 5 (597-605)DOI: 10.1182/blood-2017-03-771220);A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

Blood

Volumn 130, Issue 5, 2017, Pages 597-605

  Sanchorawala, Vaishali ^a   Palladini, Giovanni ^b   Kukreti, Vishal ^c   Zonder, Jeffrey A ^d   Cohen, Adam D ^e   Seldin, David C ^a   Dispenzieri, Angela ^f   Jaccard, Arnaud ^g   Schönland, Stefan O ^h   Berg, Deborah ⁱ   Yang, Huyuan ⁱ   Gupta, Neeraj ⁱ   Hui, Ai Min ⁱ   Comenzo, Raymond L ^j   Merlini, Giampaolo ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d KARMANOS CANCER INSTITUTE   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f MAYO CLINIC   (United States)

^g LIMOGES UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ MILLENNIUM PHARMACEUTICALS INC   (United States)

^j TUFTS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOMODULATING AGENT; IXAZOMIB; MELPHALAN; METOPROLOL; BORON DERIVATIVE; GLYCINE; PROTEASOME INHIBITOR;

ADULT; ADVERSE OUTCOME; AGED; AL AMYLOIDOSIS; ARTICLE; ATRIAL FIBRILLATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HEART ARREST; HEART FAILURE; HERPES ZOSTER; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPONATREMIA; KIDNEY FAILURE; MACULOPAPULAR RASH; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QUALITY OF LIFE; RASH; RELAPSE; RESPIRATORY FAILURE; SKIN DISEASE; SUBCUTANEOUS TISSUE DISORDER; THROMBOCYTOPENIA; AMYLOIDOSIS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FOLLOW UP; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; SURVIVAL RATE;

ADMINISTRATION, ORAL; AGED; AMYLOIDOSIS; BORON COMPOUNDS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GLYCINE; HUMANS; MALE; MIDDLE AGED; PROTEASOME INHIBITORS; SURVIVAL RATE;

EID: 85026898715     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/BLOOD.2020005086     Document Type: Erratum

References (44)

1. Comenzo RL. Managing systemic light-chain amyloidosis. J Natl Compr Canc Netw. 2007;5(2): 179-187.
2. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29(14):1924-1933.
3. Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013;121(26):5124-5130.
4. Merlini G, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA. Immunoglobulin light chain amyloidosis. Expert Rev Hematol. 2014;7(1): 143-156.
5. Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood. 2016;128(2):159-168.
6. Palladini G, Milani P, Foli A, et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica. 2014;99(4):743-750.
7. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007;109(2):465-470.
8. Palladini G, Milani P, Foli A, et al. A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. Blood. 2017;129(15):2120-2123.
9. Reece DE, Hegenbart U, Sanchorawala V, et al. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood. 2014;124(16):2498-2506.
10. Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and safety of once-weekly and twiceweekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011;118(4):865-873.
11. Sanchorawala V, Shelton AC, Lo S, Varga C, Sloan JM, Seldin DC. Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood. 2016;128(8):1059-1062.
12. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007;109(2):492-496.
13. Kaufman GP, Dispenzieri A, Gertz MA, et al. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. Am J Hematol. 2015;90(3): 181-186.
14. Gertz MA, Lacy MQ, Dispenzieri A, et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica. 2007;92(10): 1415-1418.
15. Palladini G, Russo P, Nuvolone M, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood. 2007;110(2):787-788.
16. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005; 79(4):319-328.
17. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541-4549.
18. D'Souza A, Huang J, Hari P. New light chain amyloid response criteria help risk stratification of patients by day 100 after autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(4):768-770.
19. Girnius S, Seldin DC, Cibeira MT, Sanchorawala V. New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation. J Clin Oncol. 2013;31(21): 2749-2750.
20. Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612-615.
21. Kastritis E, Roussou M, Gavriatopoulou M, et al. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. Am J Hematol. 2015;90(4):E60-E65.
22. Mahmood S, Palladini G, Sanchorawala V, Wechalekar A. Update on treatment of light chain amyloidosis. Haematologica. 2014;99(2):209-221.
23. Cohen AD, Comenzo RL. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program. 2010;2010:287-294
24. Merlini G, Palladini G. Light chain amyloidosis: the heart of the problem. Haematologica. 2013; 98(10):1492-1495.
25. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32(1):45-59.
26. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomibdexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391-4394.
27. Atrash S, Tullos A, Panozzo S, et al. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Blood Cancer J. 2015;5:e272.
28. Cohen A, Liedtke M, Scott E, et al. Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl 3): e58-e59.
29. Kumar SK, Bensinger WI, Zimmerman TM, et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood. 2014;124(7):1047-1055.
30. Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014;15(13):1503-1512.
31. Moreau P, Masszi T, Grzasko N, et al; TOURMALINE-MM1 Study Group. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17): 1621-1634.
32. Richardson PG, Baz R, Wang M, et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014;124(7): 1038-1046.
33. Ninlaro (ixazomib) capsules, for oral use [package insert]. Osaka, Japan: Takeda Pharmaceuticals Limited; 2015.
34. Gupta N, Hanley MJ, Venkatakrishnan K, et al. The effect of a high-fat meal on the pharmacokinetics of ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors or lymphoma. J Clin Pharmacol. 2016;56(10):1288-1295.
35. Gupta N, Hanley MJ, Venkatakrishnan K, et al. Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. Br J Clin Pharmacol. 2016;82(3):728-738.
36. Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325-2332.
37. Snyder CF, Blackford AL, Sussman J, et al. Identifying changes in scores on the EORTCQLQ-C30 representing a change in patients' supportive care needs. Qual Life Res. 2015;24(5): 1207-1216.
38. Gupta N, Goh YT, Min CK, et al. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. J Hematol Oncol. 2015;8:103-111.
39. Gupta N, Diderichsen PM, Hanley MJ, et al. Population pharmacokinetic analysis of ixazomib, an oral proteasome inhibitor, including data from the phase III TOURMALINE-MM1 study to inform labelling [published online ahead of print 13 March 2017]. Clin Pharmacokinet. doi: 10.1007/s40262-017-0526-4.
40. Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010; 70(5):1970-1980.
41. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem. 2000;46(5):673-683.
42. Neelam S, Kakhniashvili DG, Wilkens S, Levene SD, Goodman SR. Functional 20S proteasomes in mature human red blood cells. Exp Biol Med (Maywood). 2011;236(5):580-591.
43. Kumar S, Dispenzieri A, Katzmann JA, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 2010;116(24):5126-5129.
44. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989-995.